Inspire Medical Systems (NYSE:INSP) Stock Price Expected to Rise, Truist Financial Analyst Says

Posted by George Bondi on Oct 14th, 2026

Inspire Medical Systems (NYSE:INSP – Get Free Report) had its price objective lifted by equities researchers at Truist Financial from $62.00 to $78.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “hold” rating on the stock. Truist Financial’s price objective suggests a potential upside of 15.16% from the company’s current price.

Other analysts also recently issued research reports about the stock. KeyCorp reaffirmed a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Freedom Capital raised shares of Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. JPMorgan Chase & Co. increased their price target on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Barclays assumed coverage on shares of Inspire Medical Systems in a research report on Tuesday, October 6th. They set an “underweight” rating and a $65.00 price objective for the company. Finally, Zacks Research cut Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $68.82.

Get Our Latest Analysis on Inspire Medical Systems

Inspire Medical Systems Price Performance

INSP stock traded down $1.13 during midday trading on Wednesday, reaching $67.73. 231,847 shares of the company were exchanged, compared to its average volume of 1,067,780. Inspire Medical Systems has a one year low of $38.91 and a one year high of $147.03. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of 14.69, a price-to-earnings-growth ratio of 5.41 and a beta of 0.73. The business has a 50-day moving average price of $65.71 and a two-hundred day moving average price of $54.43.

Inspire Medical Systems (NYSE:INSP – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.38. The company had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s revenue was down 7.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, analysts anticipate that Inspire Medical Systems will post 1.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jason Kelly sold 963 shares of Inspire Medical Systems stock in a transaction on Friday, August 7th. The stock was sold at an average price of $59.55, for a total transaction of $57,346.65. Following the completion of the sale, the insider owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This trade represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Inspire Medical Systems

Several institutional investors and hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC grew its stake in Inspire Medical Systems by 1,115.4% during the first quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after buying an additional 580 shares in the last quarter. Versant Capital Management Inc increased its holdings in Inspire Medical Systems by 379.0% in the 2nd quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock valued at $43,000 after buying an additional 758 shares during the period. GAMMA Investing LLC increased its holdings in Inspire Medical Systems by 85.0% in the 2nd quarter. GAMMA Investing LLC now owns 1,221 shares of the company’s stock valued at $54,000 after buying an additional 561 shares during the period. State of Wyoming raised its position in shares of Inspire Medical Systems by 83.7% in the 1st quarter. State of Wyoming now owns 1,343 shares of the company’s stock valued at $69,000 after buying an additional 612 shares in the last quarter. Finally, Nykredit A S acquired a new position in shares of Inspire Medical Systems in the 2nd quarter valued at approximately $78,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems Company Profile

(Get Free Report)

Inspire Medical Systems, Inc is a medical technology company focused on developing and commercializing treatments for obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is the Inspire therapy system, an implantable device designed for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefits from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses an implantable pulse generator, a stimulation lead and a sensing lead.